registry – Page 38 – Communicable Diseases Research

Cutaneous Manifestations in COVID-19: Report on 31 Cases from Five Countries

Article

Published on 2021-01-132022-10-28
Journal: Biology [Category] COVID-19,

The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials

코로나19 예방을 위한 하이드록시클로로퀸의 효능 및 안전성: 무작위 임상시험에 대한 체계적인 검토 및 메타분석

Meta-Analysis

Published on 2021-01-062022-09-10
Journal: PLoS ONE [Category] 임상, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 adverse event adverse events antiviral properties antiviral property calculated CIs clinical clinical benefit Controlled controlled trials coronavirus coronavirus disease coronavirus disease-2019 Coronavirus-2 COVID-19 determine did not reduce Efficacy and safety eligibility criteria Evidence HCW Health Organization healthcare worker Healthcare workers high risk higher risk Hospitalization Hydroxychloroquine in vitro increased the risk Meta-analysis moderate Mortality outcome pharmacologic prophylaxis pharmacological physical distancing Placebo Population Prophylactic Prophylaxis Randomized controlled trial Randomized controlled trials randomized trial RCT RCTs reduce registry relative risks respiratory risk RRs SARS CoV SARS CoV-2 searched Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus solution systematic review Transmission use of hydroxychloroquine World Health Organization
[DOI] 10.1371/journal.pone.0244778 PMC 바로가기 [Article Type] Meta-Analysis

A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)

Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)

Letter

Published on 2021-01-062022-08-31
Journal: Trials [Category] MERS, 임상, 치료제,

[키워드] 1:1 administration age allergic Analysis appearance Arm ARMS assumed Asymptomatic balancing Blinding body temperature calculated capture cardiovascular disease Chain Reaction clinical clinical trials cloud condition Control control group cough COVID-19 diabetes disappearance dissemination doctor dosage dropout rate drug edema effective element Endpoint exclusion criteria failure Fever Final final analysis final analysis) Frequency group hands healthy history hospital Hospitalization hypertension hypokalaemia Hypothesis ICU Immunosuppressant immunosuppressants incidence of COVID-19 incidence rate incidence rates include inclusion criteria Infection infection rate Inflammation interim analysis interstitial pneumonia intervention group investigator Japan Japanese Kampo Kampo medicines liver dysfunction lung malaise management mechanical ventilation Medicine number numbness objective observation period oral administration oral administration) outcome package parallel-group participant Patient PCR PCR positive per day Period pharmaceutical Placebo placebo group Placebo tablets positive result power power of 80% pregnant Prevent Prophylactic prophylactic study protocol randomised Randomized Randomized controlled trial RCT receive recruited Registered Registration registry required Research respiratory respiratory diseases respiratory inflammation risk factor Risk factors Safety Sample size SARS-CoV-2 RNA secondary Secondary outcomes Shock Shortness of breath significantly skin rash sputum study drug study period Study protocol supplementary material Symptom Symptoms symptoms of COVID-19 Tablet Taking Taste the placebo group Trial Trial registration Two-arm university upper respiratory verification Viral viral infection Vital website
[DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter

Immunological alternation in COVID-19 patients with cancer and its implications on mortality

Observational Study

Published on 2021-01-042022-10-05
Journal: Oncoimmunology [Category] 임상,

[키워드] Analysis B cells Cancer CD4 CD8 cells Chinese clinical Cohort cohorts conducted COVID-19 COVID-19 infection COVID-19 patient Cox regression cytokine dysregulated immune response elevated evaluate the effect greater had more High-sensitivity C-reactive protein IL-6 IL-8 immune Immune cell immune dysregulation immune response immune system immunological immunological characteristics implication increased mortality independent risk factor Inflammatory factor investigated Logistic regression malignancy Mortality mortality rate mortality risk NK cells Patient patients patients hospitalized poor prognosis procalcitonin Prognosis receptor Registered registry regressions remained retrospective cohort study risk of COVID-19 SARS-CoV-2 significantly significantly higher Stratification susceptible T cells those without cancer with COVID-19
[DOI] 10.1080/2162402X.2020.1854424 PMC 바로가기 [Article Type] Observational Study

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

중등도에서 중증의 COVID-19(NACOVID) 치료를 위한 nitazoxanide + atazanavir/ritonavir의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Comparative Study

Published on 2021-01-042022-09-10
Journal: Trials [Category] 신약개발, 임상, 치료제,

[키워드] 1:1 24 hour 24 hours achievement addition Administered African age allocation anticipated antiretroviral drugs antiviral activity approval Atazanavir atazanavir/ritonavir Blinding Care clinical Clinical improvement Clinical management Comorbidities confirmation Control control group COVID-19 COVID-19 diagnosis COVID-19 infection criteria defined determined by diagnosed Diagnosis discharge dissemination drug Drug administration drugs Efficacy and safety element eliminated enrolment exclusion criteria food Food and Drug Administration Gender group hospital hypersensitivity include inclusion criteria Infectious diseases information initiation of treatment Interaction intervention group Isolation lactating mechanical ventilation medication moderate moderate to severe multicentre Nasopharyngeal swab negativity Nigeria nitazoxanide number objective Ogun once daily Open-label open-label trial Ordinal Scale outcome measure Pan Pan African Clinical Trials Registry participant Patient PCR PCR test Phase 2 physician polymerase chain polymerase chain reaction positive pregnant Proportion of participant protocol quantified randomisation randomised randomised controlled trial receive receiving recruited REDCap Registered registry reported Ritonavir RT-PCR Saliva Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 polymerase chain reaction SARS-CoV-2 viral load secondary care sequence severe COVID-19 specialist Standard Standard of care state Stratification Study protocol supplementary material symptomatic Teaching Temporal the WHO time Treatment Trial Trial registration university Viral Viral load website working
[DOI] 10.1186/s13063-020-04987-8 PMC 바로가기 [Article Type] Comparative Study

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

HIV 서브타입 C DNA 및 MF59-보강 서브타입 C 엔벨로프 단백질의 안전성 및 면역원성을 평가하기 위한 1상 인간 면역결핍 바이러스(HIV) 백신 시험

Articles and Commentaries

Published on 2021-01-012022-09-06
Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease,

[키워드] adjuvant administration advancement African Antibody Response antibody response rate Biojector boost CD4 cellular clinical Department DNA DNA prime/protein boost Efficacy elicited enrolled envelope envelope protein evaluate followed by glycoprotein greater healthy HIV HIV vaccine HIV-1 HIV-1 infection Human Human immunodeficiency virus Humoral response immunogenicity injected injection intramuscularly network partnership Phase 1 Placebo priming Protein Randomized regimen Registration registry response rate Result risk Safe Safety significantly significantly higher South South Africa subtype subtype C T-cell Response T-cell responses Trial vaccination Vaccine
[DOI] 10.1093/cid/ciz1239 PMC 바로가기 [Article Type] Articles and Commentaries

Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study

Observational Study

Published on 2021-01-012022-10-04
Journal: Journal of cystic fibrosis : official journal of t [Category] MERS, SARS, 임상,

[키워드] age analysed Antibiotics antiviral treatments body mass index Characteristics children clinical Clinical course co-morbidities Community Corticosteroids country COVID-19 COVID-19 disease COVID-19 illness cystic fibrosis Deterioration died expiratory fibrosis FIVE group harmonization hospital hospitalised International interquartile range less Lung disease Lung function majority male median mild illness non-invasive ventilation positive predicted reduced registry required respiratory problems Result risk factor SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease supplementary oxygen Volume
[DOI] 10.1016/j.jcf.2020.11.021 PMC 바로가기 [Article Type] Observational Study

Clinical characteristics of older patients with COVID-19: a systematic review of case reports

Original Article

Published on 2021-01-012022-10-31
Journal: Dementia & Neuropsychologia [Category] COVID-19,

[키워드] absence Adults age Aged article C-reactive protein Case report case reports case sery Characteristics Chest radiography clinical clinical condition Complete Coronavirus infections cough COVID-19 COVID-19 pandemic COVID-19 patients database decrease Dementia distress epidemiological Fever frailty hypertension Idosos increase in infecção por SARS-CoV-2 Infection information interleukin 6 Laboratory less LILACS Lymphocytes morbidity and mortality Older older patient PaO parameter Patient people with COVID-19 physiological change PubMed Central Registered registry relatos de casos reported Revisão sistemática SARS-CoV-2 searched systematic review tomography
[DOI] 10.1590/1980-57642021dn15-010001 PMC 바로가기 [Article Type] Original Article

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial

Protocol

Published on 2020-12-312022-10-29
Journal: JMIR Research Protocols [Category] COVID-19,

[키워드] administration antipyretics Baseline assessment changes in Ciclesonide clinical Clinical outcome conducted Controlled COVID-19 Data collection determine diagnosed with COVID-19 dose drug Drug administration effective Effectiveness Efficacy endpoint analysis enrolled exclusion criteria expected exploratory Fisher exact test follow-up assessment group groups hospital hypothese Identifier Inclusion Intervention investigator-initiated Japan Laboratory Limited multicenter objective Open-label parallel-group parameter participant Patient patients with COVID-19 peer-reviewed per day performed Pneumonia proposed therapy protocol Randomized Randomized controlled trial receive recruited reduction Registration registry report required Result Safe Safety SARS-CoV-2 statistically significant difference Symptomatic treatment Teijin therapeutic interventions therapeutic option therapy tomography treating Treatment treatment group Trial viral genome
[DOI] 10.2196/23830 PMC 바로가기 [Article Type] Protocol